EliTE-Symphony study recruitment begins

November 14, 2002

12 November 2002, Monte Carlo - Senior trial investigators today announced that the first person is about to be recruited into the EliTE* (Efficacy Limiting Toxicity Elimination)-Symphony Study, the largest renal transplantation trial ever to be conducted. Patient enrollment began this month and the study aims to recruit 1300 kidney transplant patients in total, from approximately 100 sites in 17 countries worldwide.

The objective of the EliTE-Symphony study will be to demonstrate that a combination of lower toxicity immunosuppressants CellCept® (mycophenolate mofetil, MMF), Zenapax® (daclizumab) and corticosteroids can enable a dose reduction of the higher toxicity immunosuppessants cyclosporine, tacrolimus or sirolimus, while simultaneously maintaining excellent efficacy. The results of this study will provide physicians with the opportunity to select an optimized immunosuppressive regimen.

Sponsor of the ELiTE-Symphony Study, Professor Henrik Ekberg, Lund University, Malmö, Sweden explained, "The focus in transplantation is now shifting. Although we are still concerned with reducing acute rejection, increasingly we are looking to develop long-term, low-toxicity treatment strategies which will result in patients retaining their transplanted organs for longer."

He continued, "With the EliTE-Symphony Study, we have the opportunity to evaluate established immunosuppressant treatment regimens that have never been compared before in such a way. We hope to show that CellCept® in combination with Zenapax® can allow for the safe reduction of combined therapies such as cyclosporine, tacrolimus or sirolimus to non-toxic levels with no loss in efficacy, and with improved long-term outcomes. It is the study which the transplant world has been waiting for and its results are likely to have a great impact on immunosuppressive regimen selection in the future."

The EliTE-Symphony Study is an independent investigator study fulfilling International Council on Harmonization (ICH) guideline requirements, sponsored by Professor Henrik Ekberg and Professor Philip F. Halloran, Edmonton, Canada and led by a steering committee of world renowned experts in the field of transplantation.
-end-
Notes to Editors:

The EliTE-Symphony Study is an open label study with 4 parallel arms:
  • Group A (control - standard immunosuppression)
    MMF + normal dose cyclosporine + corticosteroids
  • Group B
    daclizumab + MMF + low dose cyclosporine + corticosteroids
  • Group C
    daclizumab + MMF + low dose tacrolimus + corticosteroids
  • Group D
    daclizumab + MMF + low dose sirolimus + corticosteroids

  • The study will be open to either male or female single-organ renal transplant recipients (from living or cadaver donors), aged between 18 and 75 years.

  • Due to the scale of the study an automatic centralised randomisation system will be used to assign treatment arms to the patients. In addition, electronic data capture via the internet will be used to collect and to facilitate accurate patient reporting. These will ensure that ICH guidelines are followed.

  • Countries participating in the EliTE-Symphony Study include Austria, Australia, Belgium, Brazil, Canada, Czech Republic, Germany, Greece, Israel, Italy, Mexico, Poland, Spain, Sweden, Turkey, UK, USA. For further information please contact:
    Roana Mahmud
    Ketchum Healthcare, London
    Office Tel: 44-207-611-3592
    Email: roana.mahmud@ketchum.com

    Sally Cresswell
    Ketchum Healthcare, London
    Office Tel: 44-207-611-3554
    Email: sally.cresswell@ketchum.com

    Monica Shuman
    Ketchum Healthcare, London
    Office Tel: 44-207-611-3645
    Email: monica.shuman@ketchum.com

    Ketchum UK

    Related Transplantation Articles from Brightsurf:

    A revolutionary new treatment alternative to corneal transplantation
    A new approach in ophthalmology that offers a revolutionary alternative to corneal transplantation has just been developed by researchers and clinicians in North America, Europe, and Oceania.

    Fewer complications after organ transplantation
    A large international study coordinated by University Hospital Regensburg and Charité - Universitätsmedizin Berlin has demonstrated the safety of new cell therapy approaches for use in kidney transplant recipients.

    Elderly patients also benefit from kidney transplantation
    So far, kidney transplantation has generally not been offered to elderly patients (>75 years) because of the perioperative risks.

    New material will allow abandoning bone marrow transplantation
    Scientists from the National University of Science and Technology 'MISIS' developed nanomaterial, which will be able to restore the internal structure of bones damaged due to osteoporosis and osteomyelitis.

    Fewer medical tests -- timely listing for transplantation
    Younger patients would benefit greatly from kidney transplantation. Their expected remaining lifetime may even be doubled by having a transplant.

    Uterus transplantation -- ethically just as problematic as altruistic surrogacy
    In 2014, the first child to have been gestated in a donated uterus was born.

    Advancing transplantation: Hepatitis C-infected organs safe for transplantation when followed by antiviral treatment
    Twenty patients at Penn Medicine have been cured of the hepatitis C virus (HCV) following lifesaving kidney transplants from deceased donors who were infected with the disease, according to a study published today in Annals of Internal Medicine.

    Transplantation followed by antiviral therapy cured hepatitis C
    Twenty patients who received kidneys transplanted from hepatitis C virus (HCV)-infected donors experienced HCV cure, good quality of life, and excellent renal function at one year.

    The Journal of Heart and Lung Transplantation: 50 years of heart transplantation progress
    This month marks the 50th anniversary of the world's first human heart transplant performed at Groote Schuur Hospital in Cape Town by South African surgeon, Christiaan Barnard.

    Older donor lungs should be considered for transplantation
    With a scarcity of lungs available for transplantation, the use of lungs from donors older than age 60 has been shown to achieve reasonable outcomes and should be considered as a viable option, according to research published online today in The Annals of Thoracic Surgery.

    Read More: Transplantation News and Transplantation Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.